Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

被引：0
|
作者：
Lombardi, G. [1 ]
Del Bianco, P. [2 ]
Brandes, A. A. [3 ]
Eoli, M. [4 ]
Ruda, R. [5 ,6 ]
Ibrahim, T. [7 ]
Lolli, I. R. [8 ]
Pace, A. [9 ]
Daniele, B. [10 ]
Pasqualetti, F. [11 ]
Rizzato, S. [12 ]
Bergo, E. [1 ]
Caccese, M. [1 ]
Padovan, M. [1 ]
Soffietti, R. [5 ,6 ]
De Salvo, G. L. [2 ]
Zagonel, V. [1 ]
机构：
[1] IOV IRCCS, Veneto Inst Oncol, Dept Oncol, Oncol 1, Padua, Italy
[2] IOV IRCCS, Veneto Inst Oncol, Clin Res Unit, Padua, Italy
[3] AUSL IRCCS Sci Neurol, Dept Med Oncol, Bologna, Italy
[4] Besta Inst, Mol Neurooncol Unit, Milan, Italy
[5] Univ Turin, Dept Neurooncol, Turin, Italy
[6] City Hlth & Sci Hosp, Turin, Italy
[7] IRST Ist Sci Romagnolo Studio & Cura Tumori IRCCS, Med Oncol Unit, Meldola, Forli Cesena, Italy
[8] IRCCS Saverio de Bellis, Med Oncol Unit, Bari, Italy
[9] Regina Elena Canc Inst IRCCS, Neuroncol Unit, Rome, Italy
[10] AOG Rummo, Med Oncol Unit, Benevento, Italy
[11] Azienda Osped Univ, Radiotherapy Unit, Pisa, Italy
[12] Azienda Sanit Univ Integrata Udine, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
394O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HEALTH-RELATED QUALITY OF LIFE (HRQOL) EVALUATION IN THE REGOMA TRIAL: A RANDOMIZED, PHASE II CLINICAL TRIAL ANALYZING REGORAFENIB ACTIVITY IN RELAPSED GLIOBLASTOMA PATIENTS
    Lombardi, G.
    Del Bianco, P.
    Brandes, A.
    Eoli, M.
    Ruda, R.
    Ibrahim, T.
    Lolli, I.
    Pace, A.
    Daniele, B.
    Pasqualetti, F.
    Rizzato, S.
    Bergo, E.
    Caccese, M.
    Padovan, M.
    Soffietti, R.
    De Salvo, G.
    Zagonel, V.
    NEURO-ONCOLOGY, 2019, 21 : 14 - 14
  • [2] Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.
    Lombardi, Giuseppe
    Del Bianco, Paola
    Brandes, Alba Ariela
    Eoli, Marica
    Ruda, Roberta
    Ibrahim, Toni
    Lolli, Ivan
    Pace, Andrea
    Daniele, Bruno
    Pasqualetti, Francesco
    Rizzato, Simona
    Bergo, Eleonora
    Caccese, Mario
    Magni, Giovanna
    Soffietti, Riccardo
    De Salvo, Gian Luca
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients
    Lombardi, G.
    De Salvo, G. L.
    Brandes, A. A.
    Eoli, M.
    Ruda, R.
    Faedi, M.
    Lolli, I.
    Pace, A.
    Rizzato, S.
    Germano, D.
    Pasqualetti, F.
    Farina, M.
    Magni, G.
    Pambuku, A.
    Bergo, E.
    Cabrini, G.
    Indraccolo, S.
    Gardiman, M. P.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).
    Lombardi, Giuseppe
    De Salvo, Gian Luca
    Eoli, Marica
    Brandes, Alba Ariela
    Ruda, Roberta
    Faedi, Marina
    Pace, Andrea
    Lolli, Ivan
    Pasqualetti, Francesco
    Rizzato, Simona
    Germano, Domenico
    Maiello, Evaristo
    Indraccolo, Stefano
    Cabrini, Giulio
    Gardiman, Marina Paola
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).
    Lombardi, Giuseppe
    De Salvo, Gian Luca
    Ruda, Roberta
    Franceschi, Enrico
    Eoli, Marica
    Faedi, Marina
    Pace, Andrea
    Lolli, Ivan
    Rizzato, Simona
    Germano, Domenico
    Pasqualetti, Francesco
    Farina, Miriam
    Magni, Giovanna
    Bellu, Luisa
    Pambuku, Ardi
    Bergo, Eleonora
    Indraccolo, Stefano
    Gardiman, Marina Paola
    Soffietti, Riccardo
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide
    Krishna Reddy
    Laurie E. Gaspar
    Brian D. Kavanagh
    Allen Waziri
    Denise M. Damek
    Douglas Ney
    Kevin O. Lillehei
    Changhu Chen
    Journal of Neuro-Oncology, 2013, 114 : 111 - 116
  • [7] Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial
    Chang, Jane
    Ngai, Christopher
    Odom, Dawn
    Radder, Christina
    Kappeler, Christian
    Xu, Rui-hua
    Qin, Shukui
    Kim, Tae Won
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.
    Qin, Shukui
    Kim, Tae Won
    Yau, Thomas Cheung
    Ma, Brigette
    Pan, Hongming
    Xu, Jian-Ming
    Bai, Yuxian
    Wang, Liwei
    Yeh, Kun-Huei
    Bi, Feng
    Cheng, Ying
    Tuan Anh Le
    Lin, Jen-Kou
    Liu, Tianshu
    Dong, Ma
    Kappeler, Christian
    Chang, Jane
    Xu, Rui-hua
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide
    Reddy, Krishna
    Gaspar, Laurie E.
    Kavanagh, Brian D.
    Waziri, Allen
    Damek, Denise M.
    Ney, Douglas
    Lillehei, Kevin O.
    Chen, Changhu
    JOURNAL OF NEURO-ONCOLOGY, 2013, 114 (01) : 111 - 116
  • [10] Health-related quality of life in patients with glioblastoma: a randomised controlled trial
    Taphoorn, MJB
    Stupp, R
    Coens, C
    Osoba, D
    Kortmann, R
    van den Bent, MJ
    Mason, W
    Mirimanoff, RO
    Baumert, BG
    Eisenhauer, E
    Forsyth, P
    Bottomley, A
    LANCET ONCOLOGY, 2005, 6 (12) : 937 - 944
12345